Literature DB >> 31814067

Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease.

Fadi Khreish1, Florian Rosar1, Clemens Kratochwil2, Frederik Lars Giesel2, Uwe Haberkorn2,3, Samer Ezziddin4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31814067     DOI： 10.1007/s00259-019-04623-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  [18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice.

Authors:  Gaetan Van Simaeys; Gilles Doumont; Coraline De Maeseneire; Nicolas Passon; Simon Lacroix; Cédric Lentz; Arnaud Horion; Corentin Warnier; David Torres; Corentin Martens; Irina Vierasu; Dominique Egrise; Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-04       Impact factor: 9.236

2.  89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.

Authors:  Bastiaan M Privé; Yvonne H W Derks; Florian Rosar; Gerben M Franssen; Steffie M B Peters; Fadi Khreish; Mark Bartholomä; Stephan Maus; Martin Gotthardt; Peter Laverman; Mark W Konijnenberg; Samer Ezziddin; James Nagarajah; Sandra Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-21       Impact factor: 10.057

3.  Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research.

Authors:  Akintunde T Orunmuyi; Ismaheel O Lawal; Omonefe O Omofuma; Olalekan J Taiwo; Mike M Sathekge
Journal:  Ecancermedicalscience       Date:  2020-08-28

4.  Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging.

Authors:  Jyoti Roy; Margaret E White; Falguni Basuli; Ana Christina L Opina; Karen Wong; Morgan Riba; Anita T Ton; Xiang Zhang; Keith H Jansson; Elijah Edmondson; Donna Butcher; Frank I Lin; Peter L Choyke; Kathleen Kelly; Elaine M Jagoda
Journal:  Mol Imaging Biol       Date:  2021-04-23       Impact factor: 3.488

Review 5.  Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors:  Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

Review 6.  Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

Authors:  Paul Windisch; Daniel R Zwahlen; Frederik L Giesel; Eberhard Scholz; Patrick Lugenbiel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  EJNMMI Res       Date:  2021-02-19       Impact factor: 3.138

Review 7.  The Role of Theranostics in Prostate Cancer.

Authors:  Elisabeth O'Dwyer; Lisa Bodei; Michael J Morris
Journal:  Semin Radiat Oncol       Date:  2021-01       Impact factor: 5.934

Review 8.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

9.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

10.  High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.

Authors:  Claudia Kesch; Leubet Yirga; Katharina Dendl; Analena Handke; Christopher Darr; Ulrich Krafft; Jan Philipp Radtke; Stephan Tschirdewahn; Tibor Szarvas; Ladan Fazli; Martin Gleave; Frederik L Giesel; Uwe Haberkorn; Boris Hadaschik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-05       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.